| Literature DB >> 29760600 |
Neserin Ali1, Stefan Ljunggren2, Helen M Karlsson2, Aneta Wierzbicka3, Joakim Pagels3, Christina Isaxon3, Anders Gudmundsson3, Jenny Rissler3, Jörn Nielsen1, Christian H Lindh1, Monica Kåredal1.
Abstract
BACKGROUND: Epidemiological studies have shown that many welders experience respiratory symptoms. During the welding process a large number of airborne nanosized particles are generated, which might be inhaled and deposited in the respiratory tract. Knowledge of the underlying mechanisms behind observed symptoms is still partly lacking, although inflammation is suggested to play a central role. The aim of this study was to investigate the effects of welding fume particle exposure on the proteome expression level in welders suffering from respiratory symptoms, and changes in protein mediators in nasal lavage samples were analyzed. Such mediators will be helpful to clarify the pathomechanisms behind welding fume particle-induced effects.Entities:
Keywords: Chamber study; Effects; Mass spectrometry; Nasal lavage; Pathways; Proteomics; Welding fume particles
Year: 2018 PMID: 29760600 PMCID: PMC5946400 DOI: 10.1186/s12014-018-9196-y
Source DB: PubMed Journal: Clin Proteomics ISSN: 1542-6416 Impact factor: 3.988
Fig. 1Overview of study design and nasal lavage sampling. The subjects were exposed for 5.5 h to either filtered air or welding fumes at 1 mg/m3 (PM2.5). Nasal lavage fluids were collected on four occasions, twice prior to exposure and twice after. The first sample was a washout (NL 0, not analyzed), the second was the baseline sample (NL 1), which was taken 30 min after the wash out, the third sample was collected immediately at the end of exposure (NL 2), and the fourth sample was taken 18–20 h after the end of the exposure (NL 3). Two subjects had missing samples and were therefore excluded in the analysis of the pooled samples
Fig. 2Flowchart of the experiment: Nasal lavage sampling before and after exposure to welding fume particles and filtered air. (1) Protein analysis through shotgun proteomics in combination with IPA analysis generates a hypothesis of the mechanisms induced by the welding fume particle exposure. (2) Targeted protein analysis of specific proteins with label-free relative quantification and absolute quantification of MMP9, A1AT, A2MG, APOB, and elastin. (3) Statistical evaluation of the changed protein level with linear mixed model and Wilcoxon signed rank test. (4) Pathway analysis of significantly changed proteins after welding fume particle exposure compared to filtered air exposure
Significantly changed proteins from the individual samples evaluated by LMM
| AC | Gene name | Protein names | Beta value | CI 95% (min–max) | FDR | Sig. peptides | Nr. peptides |
|---|---|---|---|---|---|---|---|
|
| |||||||
| P04040 | CATA | Catalase | 2.42 | (1.46–4.02) | 1 | 2 | |
| P02766 | TTHY | Transthyretin | 1.38 | (1.02–1.86) | –f | 1 | 2 |
| P15924 | DESP | Desmoplakin | 1.37 | (1.05–1.77) | 1 | 2 | |
| A6NC86 | PINLY | Phospholipase A2 inhibitor | 1.35 | (1.09–1.66) | 1 | 1 | |
| P80188 | NGAL | Neutrophil gelatinase-associated lipocalin | 1.35 | (1.02–1.78) | –f | 2 | 3 |
| P18510 | IL1RN | Interleukin-1 receptor antagonist protein | 1.30 | (1.02–1.67) | –f | 1 | 1 |
| Q8TDL5 | LPLC1 | BPI fold-containing family B member 1 | 1.29 | (1.03–1.61) | –f,f | 2 | 2 |
| P0DJI8 | SAA1 | Serum amyloid A-1 protein | 1.28 | (1.00–1.62) | –f | 1 | 2 |
| P01023 | A2MG | Alpha-2-macroglobulin | 1.26 | (1.10–1.45) | 1 | 4 | |
| P02790 | HEMO | Hemopexin | 1.26 | (1.05–1.51) | 1 | 3 | |
| Q08380 | LG3BP | Galectin-3-binding protein | 1.26 | (1.10–1.44) | 1 | 2 | |
| P01834 | IGKC | Immunoglobulin kappa constant | 1.24 | (1.04–1.48) | 2 | 2 | |
| P05155 | IC1 | Plasma protease C1 inhibitor | 1.23 | (1.02–1.50) | –f | 1 | 3 |
| P08603 | CFAH | Complement factor H | 1.23 | (1.03–1.48) | 1 | 1 | |
| P02760 | AMBP | Protein AMBP | 1.23 | (1.04–1.46) | 1 | 2 | |
| Q92743 | HTRA1 | Serine protease HTRA1 | 1.23 | (1.10–1.37) | 1 | 2 | |
| P22894 | MMP8 | Neutrophil collagenase | 1.22 | (1.08–1.38) | 1 | 1 | |
| P07737 | PROF1 | Profilin-1 | 1.20 | (1.00–1.43) | –f | 1 | 1 |
| P27169 | PON1 | Serum paraoxonase | 1.20 | (1.11–1.29) | 1 | 3 | |
| P10909 | CLUS | Clusterin | 1.19 | (1.11–1.28) | 2 | 3 | |
| Q96DA0 | ZG16B | Zymogen granule protein 16 homolog B | 1.18 | (1.03–1.37) | 1 | 1 | |
| P04792 | HSPB1 | Heat shock protein beta-1 | 1.16 | (1.01–1.34) | –f | 1 | 2 |
|
| |||||||
| P07602 | SAP | Prosaposin | 0.92 | (0.88–0.97) | 1 | 3 | |
| Q9GZX6 | IL22 | Interleukin-22 | 0.88 | (0.79–0.99) | –f | 1 | 3 |
| P01034 | CYTC | Cystatin-C | 0.88 | (0.79–0.97) | 1 | 1 | |
| Q9Y624 | JAM1 | Junctional adhesion molecule A | 0.87 | (0.77–0.97) | 1 | 2 | |
| Q13822 | ENPP2 | Ectonucleotide pyrophosphatase | 0.85 | (0.74–0.97) | 1 | 1 | |
| O75223 | GGCT | Gamma-glutamylcyclotransferase | 0.82 | (0.73–0.93) | 1 | 3 | |
| P37802 | TAGL2 | Transgelin-2 | 0.82 | (0.70–0.95) | 1 | 1 | |
| Q14118 | DAG1 | Dystroglycan | 0.81 | (0.66–1.00) | –f | 1 | 2 |
| P04080 | CYTB | Cystatin-B | 0.81 | (0.71–0.92) | 1 | 1 | |
| P02751 | FINC | Fibronectin | 0.80 | (0.66–0.97) | 1 | 3 | |
| P14780 | MMP9 | Matrix metalloproteinase-9 | 0.78 | (0.62–0.97) | –f | 2 | 3 |
| P31944 | CASPE | Caspase-14 | 0.77 | (0.62–0.95) | 2 | 2 | |
| P05164 | PERM | Myeloperoxidase | 0.75 | (0.62–0.92) | –f | 2 | 2 |
| Q14019 | COTL1 | Coactosin-like protein | 0.72 | (0.58–0.89) | 1 | 2 | |
| P06727 | APOA4 | Apolipoprotein A-IV | 0.71 | (0.54–0.93) | 1 | 3 | |
| P01033 | TIMP1 | Metalloproteinase inhibitor 1 | 0.71 | (0.57–0.88) | 1 | 2 | |
| O75594 | PGRP1 | Peptidoglycan recognition protein 1 | 0.70 | (0.54–0.90) | 3 | 3 | |
| P29401 | TKT | Transketolase | 0.69 | (0.50–0.94) | 1 | 2 | |
| P04406 | G3P | Glyceraldehyde-3-phosphate dehydrogenase | 0.68 | (0.57–0.81) | 1 | 1 | |
| O75556 | SG2A1 | Mammaglobin-B | 0.67 | (0.47–0.96) | –f | 1 | 3 |
| P02749 | APOH | Beta-2-glycoprotein 1 | 0.65 | (0.49–0.86) | –f | 2 | 2 |
| P01008 | ANT3 | Antithrombin-III | 0.53 | (0.31–0.89) | 1 | 1 | |
| Q6UWW0 | LCN15 | Lipocalin-15 | 0.43 | (0.25–0.72) | 1 | 2 | |
| P08670 | VIME | Vimentin | 0.72 | (0.54–0.95) | 1 | 2 | |
Relative quantification of individual samples generated this protein list of the significantly changed proteins after welding fume exposure compared to filtered air, and these were evaluated by LMM, p < 0.05. The beta value represents the average change of the protein level after welding fume exposure
f Peptides not significantly changed after multiple test correction (FDR), p > 0.03. Sig. peptides number of significantly changed peptides. Nr. Peptides number of peptides used in the SRM method representing the specific protein
Significantly changed proteins from the individual samples evaluated with Wilcoxon signed rank test
| AC | Gene name | Protein name | After exposure | Day after exposure | Significant peptides | FDR |
|---|---|---|---|---|---|---|
|
| ||||||
| P02765 | FETUA | Alpha-2-HS-glycoprotein | Increase | 1 | –f | |
|
| ||||||
| A6NC86 | PINLY | Phospholipase A2 inhibitor | Increase | Increase | 1 | |
| P01019 | ANGT | Angiotensinogen | Increase | Increase | 1 | –f |
| P01834 | IGKC | Immunoglobulin kappa constant | Increase | Increase | 2 | |
| P01857 | IGHG1 | Immunoglobulin heavy constant gamma 1 | Increase | Increase | 1 | |
| P02768 | ALBU | Serum albumin | Increase | Increase | 2 | |
| P26038 | MOES | Moesin | Increase | Increase | 1 | |
| Q92743 | HTRA1 | Serine protease HTRA1 | Increase | Increase | 1 | |
|
| ||||||
| P01023 | A2MG | Alpha-2-macroglobulin | Increase | 2 | ||
| P01859 | IGHG2 | Immunoglobulin heavy constant gamma 2 | Increase | 1 | –f | |
| P02760 | AMBP | Protein AMBP | Increase | 1 | –f | |
| P02787 | TRFE | Serotransferrin | Increase | 1 | –f | |
| P02790 | HEMO | Hemopexin | Increase | 1 | ||
| P04040 | CATA | Catalase | Increase | 1 | ||
| P04792 | HSPB1 | Heat shock protein beta-1 | Increase | 1 | ||
| P07737 | PROF1 | Profilin-1 | Increase | 1 | –f | |
| P08123 | CO1A2 | Collagen alpha-2 | Increase | 1 | –f | |
| P08603 | CFAH | Complement factor H | Increase | 1 | ||
| P15924 | DESP | Desmoplakin | Increase | 1 | –f | |
| P18510 | IL1RA | Interleukin-1 receptor antagonist protein | Increase | 1 | –f | |
| P27169 | PON1 | Serum paraoxonase | Increase | 1 | ||
| P31947 | 1433S | 14-3-3 protein sigma | Increase | 1 | ||
| P36955 | PEDF | Pigment epithelium-derived factor | Increase | 1 | ||
| Q04118 | PRB3 | Basic salivary proline-rich protein 3 | Increase | 1 | –f | |
| Q07157 | ZO1 | Tight junction protein ZO-1 | Increase | 1 | –f | |
| P11684 | UTER | Uteroglobin | Increase | 2 | ||
|
| ||||||
| P07602 | SAP | Prosaposin | Decrease | Increase | 2 | –f,f |
| Q96IY4 | CBPB2 | Carboxypeptidase B2 | Decrease | Increase | 2 | |
| P01877 | IGHA2 | Immunoglobulin heavy constant alpha 2 | Decrease | Increase | 1 | –f |
|
| ||||||
| O75556 | SG2A1 | Mammaglobin-B | Decrease | 1 | ||
| P01008 | ANT3 | Antithrombin-III | Decrease | 1 | ||
| P01034 | CYTC | Cystatin-C | Decrease | 2 | ||
| P01036 | CYTS | Cystatin-S | Decrease | 1 | ||
| P04406 | G3P | Glyceraldehyde-3-phosphate dehydrogenase | Decrease | 1 | ||
| P0DMV9 | HS71B | Heat shock 70 kDa protein 1B | Decrease | 1 | ||
| P13796 | PLSL | Plastin-2 | Decrease | 1 | ||
| P14780 | MMP9 | Matrix metalloproteinase-9 | Decrease | 1 | ||
| P15311 | EZRI | Ezrin | Decrease | 1 | ||
| P15502 | ELN | Elastin | Decrease | 1 | ||
| P37802 | TAGL2 | Transgelin-2 | Decrease | 1 | ||
| Q13822 | ENPP2 | Ectonucleotide pyrophosphatase | Decrease | 1 | ||
| Q14019 | COTL1 | Coactosin-like protein | Decrease | 1 | ||
| Q14508 | WFDC2 | WAP four-disulfide core domain protein 2 | Decrease | 1 | ||
| Q9GZZ8 | LACRT | Extracellular glycoprotein lacritin | Decrease | 1 | ||
| Q9Y624 | JAM1 | Junctional adhesion molecule A | Decrease | 1 | ||
| P04080 | CYTB | Cystatin-B | Decrease | 1 | ||
| Q6UXB2 | VCC1 | C-X-C motif chemokine 17 | Decrease | 1 | ||
| Q6P5S2 | CF058 | Protein LEG1 homolog | Decrease | 2 | –f,f | |
|
| ||||||
| O75594 | PGRP1 | Peptidoglycan recognition protein 1 | Decrease | Decrease | 2 | |
| P05164 | PERM | Myeloperoxidase | Decrease | Decrease | 2 | |
| P06727 | APOA4 | Apolipoprotein A-IV | Decrease | Decrease | 1 | –f |
|
| ||||||
| P02749 | APOH | Beta-2-glycoprotein 1 | Decrease | 1 | –f | |
| P02751 | FINC | Fibronectin | Decrease | 1 | ||
| P08311 | CATG | Cathepsin G | Decrease | 1 | ||
| P20061 | TCO1 | Transcobalamin-1 | Decrease | 1 | –f | |
| Q6UWW0 | LCN15 | Lipocalin-15 | Decrease | 1 | –f | |
Relative quantification of individual samples generated this list of the significantly changed proteins after welding fume exposure compared to filtered air, and these were statistically evaluated with the Wilcoxon signed rank test both immediately after exposure and the day after exposure, p < 0.05
f Peptides not significantly changed after multiple test correction (FDR), p > 0.036
Absolute quantification of individual sample
| Protein | Mean slope in NL | Mean slope in MilliQ water | LOD (fmol/µL) | Exposure | Mean; median; (max–min) concentration (fmol/µL) | Statistical evaluation | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Before exposure | After exposure | Day after exposure | Beta-value | 95% CI | ||||||
| MMP9 | 0.291 | 0.275 | 0.043 | A | 0.26; 0.14; (0.02–0.61) | 0.14; 0.13; (0.02–0.37) | 0.19; 0.13; (0.02–0.36) | 0.77 | 0.63–0.93 | 0.015 |
| B | 0.16; 0.15; (0.02–0.42) | 0.16; 0.11 (0.03–0.52) | 0.18; 0.16; (0.08–0.4) | |||||||
| A1AT | 0.153 | 0.158 | 0.205 | A | 0.51; 0.37; (0.23–1.28) | 0.50; 0.37; (0.23–1.6) | 0.44; 0.52; (0.14–0.94) | 1.20 | 0.77–1.87 | 0.369 |
| B | 0.67; 0.51; (0.3–2.12) | 0.52; 0.41; (0.21–1.84) | 0.56; 0.45; (0.2–1.48) | |||||||
| A2 MG | 0.184 | 0.153 | 0.075 | A | 0.52; 0.43; (0.09–0.13) | 0.42; 0.20; (0.08–1.32) | 0.35; 0.29; (0.05–0.95) | 0.95 | 0.73–1.23 | 0.669 |
| B | 0.49; 0.32; (0.16–1.13) | 0.47; 0.24; (0.09–1.55) | 0.48; 0.51; (0.11–1.44) | |||||||
| APOB | 0.164 | 0.177 | 0.356 | A/B | NA | NA | NA | – | – | – |
| Elastin | 0.432* | 0.339 | 0.339 | A/B | NA | NA | NA | – | – | – |
Mean slope of the calibration curve for each quantitative protein and the calculated LOD (determined from blank samples)
NL nasal lavage, A welding fume particle exposure, B filtered air exposure, NA no quantitative data could be obtained
* Big variation between the slopes
Fig. 3Correlation between the MMP9 concentration (fmol/µL) and lung function (FVC and FEV1%) aCombining the data from both the welding fume exposure day and filtered air exposure day. *Correlation is significant at the 0.05 level (2-tailed). **Correlation is significant at the 0.01 level (2-tailed)
Pathways associated with welding fume exposure
| Symbol | Protein | AC | Expr. fold change | Expected |
|---|---|---|---|---|
|
| ||||
| AMBP | Alpha-1-microglobulin/bikunin precursor | P02760 | 1.23 | Up |
| APOA4 | Apolipoprotein A4 | P06727 | − 1.41 | Up |
| APOH | Apolipoprotein H | P02749 | − 1.54 | Up |
| CLU | Clusterin | P10909 | 1.19 | Up |
| HPX | Hemopexin | P02790 | 1.26 | Up |
| IL1RN | Interleukin 1 receptor antagonist | P18510 | 1.30 | Down |
| MMP9 | Matrix metallopeptidase 9 | P14780 | − 1.29 | Down |
| PON1 | Paraoxonase 1 | P27169 | 1.20 | Up |
| SAA1 | Serum amyloid A1 | P0DJI8 | 1.28 | Up |
| TTR | Transthyretin | P02766 | 1.38 | Up |
|
| ||||
| A2M | Alpha-2-macroglobulin | P01023 | 1.27 | Up |
| AMBP | Alpha-1-microglobulin/bikunin precursor | P02760 | 1.23 | Down |
| APOH | Apolipoprotein H | P02749 | − 1.54 | Down |
| FN1 | Fibronectin 1 | P02751 | − 1.25 | Up |
| HPX | Hemopexin | P02790 | 1.26 | Up |
| IL1RN | Interleukin 1 receptor antagonist | P18510 | 1.30 | Up |
| SAA1 | Serum amyloid A1 | P0DJI8 | 1.28 | |
| SERPING1 | Serpin family G member 1 | P05155 | 1.24 | |
| TTR | Transthyretin | P02766 | 1.38 | Down |
The significantly changed proteins found with the LMM statistical method showed that these canonical pathways were activated due to welding fume exposure. AC: accession number. Expected: The changed direction of the protein for this canonical pathway to be activated are expected to go in e certain direction when its activated
Fig. 4Network of the significantly changed proteins and the upstream regulators. The significantly changed proteins from the LMM table were associated with the upstream regulators IL6, estrogen receptor, H1FA, IFNG, IL1B, NEUROG1, SPP1, SYVN1, TGFB1, TNF, and STAT3. The canonical pathways connected to these molecular regulators included glucocorticoid receptor signaling. Biomarker enrichment of this network connection showed connections to cystic fibrosis, chronic obstructive pulmonary disease, and asthma. Red = increased measurement, Green = decreased measurement, Orange = indicated activated, Blue = indicated inhibited